<DOC>
	<DOCNO>NCT00464373</DOCNO>
	<brief_summary>The aim randomize placebo-controlled study demonstrate efficiency safety injection Botulinum Toxin Type A ( 200 Units ) external urethral sphincter treatment chronic prostatitis/chronic pelvic pain .</brief_summary>
	<brief_title>Botulinum Toxin Type A Treatment Male Chronic Pelvic Pain Syndrome</brief_title>
	<detailed_description>The treatment male CP/CPPS often unsuccessful frustrate patient doctor . Because patient change general practitioner urologists quite regularly . One major problem unknown pathomechanism disease . Most patient suffer irritative voiding symptom dysfunction pelvic floor . By look various ( non- ) conservative therapeutical strategy become quite clear unique convince therapeutical strategy . At present Botulinum-Toxin Type A ( BTX A ) widely use urological field especially para-/tetraplegics patient trouble neurogenic bladder dysfunction . It report case series ( dos : 200U 30U ) BTX A injected external urethral sphincter able reduce symptom without provoke incontinence . This implied hypothesis obstructive voiding symptom CP/CPPS associate incomplete relaxation bladder neck external urethral sphincter . After give informed consent , patient undergo screen visit baseline evaluation include patient history , clinical examination , NIH-CPSI IPSS-questionnaires , micturition diary , sonography , 4-glass test urodynamics . Patients fulfil study eligibility criterion randomize receive intrasphincteric injection either BTX A placebo . There 5 follow-up visit include post-treatment follow-up 1 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Somatoform Disorders</mesh_term>
	<mesh_term>Pelvic Pain</mesh_term>
	<mesh_term>Prostatitis</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>CPPS NIH III ( symptom 3 month last 6 month , 4 glasstest ) Pain Score ≥ 4 During last month : intake antibiotic , alpha receptor blocker , anticholinergic ; intake analgesic contain opioids ( longer 4 day ) ; participate different clinical trial During last 3 month : document urinary infection , epididymitis , positive urinary culture ; status post biopsy prostate gland ; STD : Gonorrhea , Chlamydia , Mycoplasm , Trichomonads During last 6 month : Finasteride 5αreductase inhibitor During last 12 month : status post surgery prostate gland ; genital herpes ; adjustable hypertension , angina pectoris , heart failure ( NYHA IIIIV ) , Status post myocardial infarction , coronary bypass surgery coronary dilatation During last 24 month : cerebral insult , TIA ; active disease liver Other urological disease like prostate cancer , bladder cancer , status post radiation small pelvis , chemotherapy ( intravesical systemic ) Urinary catheter Residual urine &gt; 200ml Serum creatinine &gt; 200µmol/l Status post injection BTX A , hypersensitivity concern substance content BTX , myasthenia gravis Any kind cancer Active inflammation ( except prostate gland ) Neurological psychological disease make signing consent form behave accord study protocol impossible Abuse drug alcohol last 5 year Any disease may influence result accord opinion medical doctor</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Prostatitis</keyword>
	<keyword>Chronic Prostatitis Chronic Pelvic Pain Syndrome</keyword>
	<keyword>Botulinum Toxin Type A</keyword>
	<keyword>Drug therapy</keyword>
	<keyword>Injections , intramuscular</keyword>
</DOC>